Bridgeway Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Bridgeway Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$609K	Sell	130,900 -17,500	-12%	-$87K	0.01%	812
2026 Q1	$798K	Hold	148,400	–	–	0.02%	743
2025 Q4	$530K	Buy	148,400 +5,300	+4%	+$16.8K	0.01%	812
2025 Q3	$415K	Hold	143,100	–	–	0.01%	842
2025 Q2	$515K	Hold	143,100	–	–	0.01%	774
2025 Q1	$428K	Buy	143,100 +109,800	+330%	+$343K	0.01%	772
2024 Q4	$112K	Buy	+33,300	New	+$111K	﹤0.01%	1099
2023 Q4	–	Sell	-379,912	Closed	-$1.14M	–	1364
2023 Q3	$1.14M	Hold	379,912	–	–	0.03%	673
2023 Q2	$1.42M	Hold	379,912	–	–	0.03%	646
2023 Q1	$1.27M	Sell	379,912 -8,000	-2%	-$32.5K	0.03%	672
2022 Q4	$1.87M	Buy	387,912 +32,300	+9%	+$163K	0.05%	568
2022 Q3	$2.02M	Buy	355,612 +8,000	+2%	+$61.2K	0.05%	520
2022 Q2	$2.47M	Buy	347,612 +320,912	+1,202%	+$2.19M	0.06%	475
2022 Q1	$193K	Buy	+26,700	New	+$181K	﹤0.01%	1175

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bridgeway Capital Management's AVIR Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Atea Pharmaceuticals (AVIR) stake by 12% in Q2 2026, selling an estimated $87K and leaving 130,900 shares worth $609K. The position accounts for 0.01% of the portfolio, ranked #812.

Bridgeway Capital Management first reported a position in AVIR in Q1 2022 and has held it in 14 quarters since. The position peaked at $2.47M in Q2 2022. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Bridgeway Capital Management held 130,900 shares of Atea Pharmaceuticals worth $609K as of Q2 2026.
Bridgeway Capital Management sold 17,500 Atea Pharmaceuticals shares in Q2 2026, an estimated $87K.
Atea Pharmaceuticals made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #812 holding.
Bridgeway Capital Management first reported a position in Atea Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
Bridgeway Capital Management's Atea Pharmaceuticals position peaked at $2.47M in Q2 2022.
125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.